Three Immunomarker Support Vector Machines–Based Prognostic Classifiers for Stage IB Non–Small-Cell Lung Cancer
Authors:
- 1 March 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (7) , 1091-1099
Abstract
Purpose: Approximately 30% of patients with stage IB non–small-cell lung cancer (NSCLC) die within 5 years after surgery. Current staging methods are inadequate for predicting the prognosis of this particular subgroup. This study identifies prognostic markers for NSCLC. Patients and Methods: We used computer-generated random numbers to study 148 paraffin-embedded specimens for immunohistochemical analysis. We studied gene expression in paraffin-embedded specimens of lung cancer tissue from 73 randomly selected patients with stage IB NSCLC who had undergone radical surgical resection and evaluated the association between the level of expression and survival. We used support vector machines (SVM)–based methods to develop three immunomarker-SVM–based prognostic classifiers for stage IB NSCLC. For validation, we used randomly assigned specimens from 75 other patients. Results: We devised three immunomarker-SVM–based prognostic classifiers, including SVM1, SVM2, and SVM3, to refine prognosis of stage IB NSCLC successfully. The SVM1 model integrates age, cancer cell type, and five markers, including CD34MVD, EMA, p21ras, p21WAF1, and tissue inhibitors of metalloproteinases (TIMP) –2. The SVM2 model integrates age, cancer cell type, and 19 markers, including BCL2, caspase-9, CD34MVD, low-molecular-weight cytokeratin, high-molecular-weight cytokeratin, cyclo-oxygenase-2, EMA, HER2, matrix metalloproteinases (MMP) –2, MMP-9, p16, p21ras, p21WAF1, p27kip1, p53, TIMP-1, TIMP-2, vascular endothelial growth factor (VEGF), and β-catenin. The SVM3 model consists of SVM1 and SVM2. The three models were independent predictors of overall survival. We validated the classifiers with data from an independent cohort of 75 patients with stage IB NSCLC. Conclusion: The three immunomarker-SVM–based prognostic characteristics are closely associated with overall survival among patients with stage IB NSCLC.Keywords
This publication has 24 references indexed in Scilit:
- Gene Expression Profiling Reveals Reproducible Human Lung Adenocarcinoma Subtypes in Multiple Independent Patient CohortsJournal of Clinical Oncology, 2006
- RETRACTED: A Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Unique microRNA molecular profiles in lung cancer diagnosis and prognosisCancer Cell, 2006
- Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphomaLeukemia & Lymphoma, 2005
- Joint analysis of two microarray gene-expression data sets to select lung adenocarcinoma marker genesBMC Bioinformatics, 2004
- Gene expression-based, individualized outcome prediction for surgically treated lung cancer patientsOncogene, 2004
- A molecular signature of metastasis in primary solid tumorsNature Genetics, 2002
- Gene-expression profiles predict survival of patients with lung adenocarcinomaNature Medicine, 2002
- Diversity of gene expression in adenocarcinoma of the lungProceedings of the National Academy of Sciences, 2001
- Revisions in the International System for Staging Lung CancerChest, 1997